On May 28, 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, reported that eight abstracts featuring data derived from testing with its Decipher Prostate and Decipher Bladder genomic classifiers will be presented at ASCO (Free ASCO Whitepaper), the annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), being held May 30-June 3 in Chicago (Press release, Veracyte, MAY 28, 2025, View Source [SID1234653452]). Key findings shed new light on which patients with prostate or bladder cancer may be more likely to respond to specific therapies based on their tumors’ molecular make-up.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These new findings underscore the power of our whole-transcriptome-based Decipher GRID, or Genomic Resource for Intelligent Discovery, research tool to help advance understanding of urologic cancers at the molecular level," said Phil Febbo, M.D., Veracyte’s chief scientific officer and chief medical officer. "We are pleased to share this resource with the research community to help reveal new insights that could one day enable more-personalized care and outcomes for patients with prostate or bladder cancer."
The following Decipher Prostate GRID-focused abstract will be shared in a podium presentation at the McCormick Place convention center:
Title:
Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): an ancillary study of the STAMPEDE trials.
Presenter:
Emily Grist, Ph.D., University College London Cancer Institute
Format:
Oral Abstract Presentation
Abstract #:
5003
Date/Time:
Tuesday, June 3; 9:45 a.m. – 12:45 p.m. CDT
Room:
Hall D
Researchers found that patients whose metastatic prostate cancer had a PTEN-inactive gene expression signature were more likely to benefit from the addition of the chemotherapy, docetaxel, to standard androgen deprivation therapy (ADT), compared to those with PTEN-active tumors. Specifically, the PTEN-inactive patients had a 43% reduction in risk of death (HR=0.57, 95% 0.42-0.76), unlike PTEN-active patients where no benefit from docetaxel was observed (HR=1.05, 95% CI 0.77-1.43), with a significant interaction observed between docetaxel and PTEN status (p=0.002). Additionally, docetaxel benefited patients with PTEN-inactive tumors regardless of whether they had high- or low-volume prostate cancer. Finally, patients with tumors that were both PTEN-inactive and had high Decipher Prostate test risk scores had the greatest benefit from the addition of chemotherapy.
The study involved 832 patients with metastatic prostate cancer who were followed for a median of 14 years as part of STAMPEDE—a large, multi-center, randomized Phase 3 clinical trial that aims to determine the best way to treat men with newly diagnosed advanced or metastatic prostate cancer. Previously presented data showed that patients with high Decipher Prostate Genomic Classifier risk scores were more likely to benefit from the addition of docetaxel to ADT, compared to those with low Decipher test scores.1
"It’s well known that adding docetaxel to ADT increases survival for some patients with metastatic prostate cancer. The challenge has been knowing which patients will benefit and which ones will not so the latter can avoid unnecessary toxicity," said Emily Grist, Ph.D., of the University College London Cancer Institute who will present the new findings at the ASCO (Free ASCO Whitepaper) meeting. "Our results help to further elucidate molecular features of advanced prostate cancer, which may help us better select treatments for our patients."
The following Decipher Bladder GRID-focused abstract will be shared in a podium presentation at the ASCO (Free ASCO Whitepaper) meeting:
Title:
First results of SURE-02: A Phase 2 study of Neoadjuvant Sacituzumab Govitecan (SG) plus Pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant Pembro, in patients with muscle-invasive bladder cancer (MIBC)
Presenter:
Andrea Necchi, M.D., IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy
Format:
Rapid Oral Abstract Presentation
Abstract #:
4518
Date/Time:
Saturday, May 31; 1:15 – 2:45 p.m. CDT
Room:
Arie Crown Theater
This study evaluated whether patients with muscle-invasive bladder cancer (MBIC) could potentially benefit from treatment with Sacituzumab Govitecan (SG) plus Pembrolizumab (Pembro), rather than standard-of-care chemotherapy, prior to radical cystectomy (RC). It also used the Decipher Bladder GRID research tool to identify patients who were more likely to achieve clinical complete response (cCR), based on the molecular underpinnings of their tumor.
"Interim results from SURE-02 trial revealed that neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, followed by bladder sparing in complete responders and maintenance pembrolizumab was a safe and effective strategy in patients with MIBC," said Andrea Necchi, M.D., of IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University in Milan, Italy, who presented the findings. "Preliminary biomarker data developed by Veracyte as part of its Decipher Bladder test and GRID research tool, revealed associations between Luminal subtype and clinical complete response, or cCR, and immune signatures linked to the EFS gene that could ultimately help improve outcomes in molecularly-selected patients."
A more complete list of Decipher-focused abstracts to be presented at the ASCO (Free ASCO Whitepaper) meeting can be found on Veracyte’s website here.
About Decipher GRID
The Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its partners to contribute to continued research and help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis. More information about Decipher GRID can be found here.
About Decipher Prostate
The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients across the full spectrum of prostate cancer. The test is performed on biopsy or surgically resected samples and conveys the aggressiveness of the cancer. For patients with localized or regional prostate cancer, the Decipher score indicates a patient’s risk of metastasis, helping to determine treatment timing and intensity. For patients with metastatic prostate cancer, the Decipher score indicates the likelihood of cancer progression and survival benefit with treatment intensification. Armed with this information, physicians can better personalize their patients’ care. The Decipher Prostate test’s performance and clinical utility has been demonstrated in over 90 studies involving more than 200,000 patients. It is the only gene expression test to achieve "Level I" evidence status and inclusion in the risk-stratification table in the most recent NCCN Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found here.
About Decipher Bladder
The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here.